MPO and myocardial ischemia: Most importantly, high oral dosing with SCN−, a competitive MPO substrate, protected against myocardial ischemia/reperfusion injury in male Sprague Dawley rats by impairing infarct size and decreasing mAb recognition of HOCl-damaged myocardial proteins generated via the MPO-H2O2-Cl− system of activated neutrophils [243].